{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:57:34Z","timestamp":1789124254495,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Appl Genetics"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Apart from the driver mutations, high molecular risk (HMR) variants and other factors have been reported to influence the prognosis of primary myelofibrosis (PMF). The aim of our study was to investigate the impact of laboratory and molecular characteristics at the time of diagnosis (TOD) on the PMF outcome. The study group consisted of 82 patients recruited from three Polish university centers. Among the driver mutations, only <jats:italic>CALR<\/jats:italic> type 1 positively influenced the overall survival (OS). The risk of progression to accelerated or blastic disease phase (AP\/BP) did not depend on the driver mutation type, but was closely associated with the presence of HMR variants (<jats:italic>p<\/jats:italic>\u2009=\u20090.0062). The risk of death (ROD) was higher in patients with HMR variants (OR[95%CI]\u2009=\u20094.33[1.52;12.34], <jats:italic>p<\/jats:italic>\u2009=\u20090.0044) and in patients with a platelet count at the TOD between 50\u2013100 G\/L (HR[95%CI]\u2009=\u20092.66[1.11;6.35]) and\u2009&lt;\u200950 G\/L (HR[95%CI]\u2009=\u20098.44[2.50;28.44]). Median survival time was 7.8, 2.2 and 1.4\u00a0years in patients with large unstained cells (LUC) count of [0.0\u20130.2], (0.2\u20130.4] and\u2009&gt;\u20090.4 G\/L at the TOD, respectively. We found an unexpected, hitherto undescribed, association between LUC count at the TOD and PMF prognosis. Our analysis led to the following conclusions: in PMF patients at the TOD 1) the presence of HMR variants, especially combined, is associated with an increased risk of progression to the AP and BP, and shorter OS, 2) severe thrombocytopenia confers worse prognosis than the moderate one, 3) LUC count is closely related with the disease phase, and associated with the ROD and OS.<\/jats:p>","DOI":"10.1007\/s13353-023-00771-x","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T02:01:37Z","timestamp":1690596097000},"page":"479-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3734-271X","authenticated-orcid":false,"given":"Zuzanna","family":"Kandu\u0142a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4656-9318","authenticated-orcid":false,"given":"Micha\u0142","family":"Janowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-2583","authenticated-orcid":false,"given":"Barbara","family":"Wi\u0119ckowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7052-9741","authenticated-orcid":false,"given":"Edyta","family":"Paczkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Mroczkowska-B\u0119karciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0781-8668","authenticated-orcid":false,"given":"Marta","family":"Sobas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-2020","authenticated-orcid":false,"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,29]]},"reference":[{"key":"771_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"771_CR2","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/ejh.13579","volume":"106","author":"S Bartels","year":"2021","unstructured":"Bartels S, Vogtmann J, Schipper E et al (2021a) Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression. Eur J Haematol 106:520\u2013528. https:\/\/doi.org\/10.1111\/ejh.13579","journal-title":"Eur J Haematol"},{"key":"771_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/CYTO.1070","volume":"46","author":"A Bononi","year":"2001","unstructured":"Bononi A, Lanza F, Dabusti M et al (2001) Increased myeloperoxidase index and large unstained cell values can predict the neutropenia phase of cancer patients treated with standard dose chemotherapy. Cytometry 46:92\u201397. https:\/\/doi.org\/10.1002\/CYTO.1070","journal-title":"Cytometry"},{"key":"771_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/CYTO.B.20476","volume":"76B","author":"A Bononi","year":"2009","unstructured":"Bononi A, Lanza F, Ferrari L et al (2009) Predictive value of hematological and phenotypical parameters on postchemotherapy leukocyte recovery. Cytom Part B Clin Cytom 76B:328\u2013333. https:\/\/doi.org\/10.1002\/CYTO.B.20476","journal-title":"Cytom Part B Clin Cytom"},{"key":"771_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1515\/TJB-2017-0042\/MACHINEREADABLECITATION\/RIS","volume":"43","author":"I Cakir","year":"2018","unstructured":"Cakir I, Cakir N, Atalay MA, Koc AN (2018) Large unstained cells are correlated with inflammatory biomarkers in patients with invasive aspergillosis. Turk J Biochem 43:306\u2013311. https:\/\/doi.org\/10.1515\/TJB-2017-0042\/MACHINEREADABLECITATION\/RIS","journal-title":"Turk J Biochem"},{"key":"771_CR6","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/BLOOD-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895\u20132901. https:\/\/doi.org\/10.1182\/BLOOD-2008-07-170449","journal-title":"Blood"},{"key":"771_CR7","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","volume":"30","author":"F Cervantes","year":"2012","unstructured":"Cervantes F, Dupriez B, Passamonti F et al (2012) Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 30:2981\u20132987. https:\/\/doi.org\/10.1200\/JCO.2012.42.0240","journal-title":"J Clin Oncol"},{"key":"771_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R et al (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392\u2013397. https:\/\/doi.org\/10.1200\/JCO.2010.32.2446","journal-title":"J Clin Oncol"},{"key":"771_CR9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","volume":"145","author":"V Gelsi-Boyer","year":"2009","unstructured":"Gelsi-Boyer V, Trouplin V, Ad\u00e9la\u00efde J et al (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145:788\u2013800. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07697.x","journal-title":"Br J Haematol"},{"issue":"28","key":"771_CR10","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/leu.2014.76","volume":"289","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Lasho TL, Rotunno G et al (2014) The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 289(28):1804\u20131810. https:\/\/doi.org\/10.1038\/leu.2014.76","journal-title":"Leukemia"},{"key":"771_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/bjh.14601","volume":"181","author":"J-C Hern\u00e1ndez-Boluda","year":"2018","unstructured":"Hern\u00e1ndez-Boluda J-C, Correa J-G, Alvarez-Larr\u00e1n A et al (2018) Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. Br J Haematol 181:397\u2013400. https:\/\/doi.org\/10.1111\/bjh.14601","journal-title":"Br J Haematol"},{"key":"771_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/BJH.18440","volume":"199","author":"JC Hern\u00e1ndez-Boluda","year":"2022","unstructured":"Hern\u00e1ndez-Boluda JC, Pastor-Gal\u00e1n I, Arellano-Rodrigo E et al (2022) Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis. Br J Haematol 199:529\u2013538. https:\/\/doi.org\/10.1111\/BJH.18440","journal-title":"Br J Haematol"},{"key":"771_CR13","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1002\/CNCR.23505","volume":"112","author":"J Huang","year":"2008","unstructured":"Huang J, Li CY, Mesa RA et al (2008) Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 112:2726\u20132732. https:\/\/doi.org\/10.1002\/CNCR.23505","journal-title":"Cancer"},{"key":"771_CR14","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/LEU.2013.219","volume":"27","author":"JV Jovanovic","year":"2013","unstructured":"Jovanovic JV, Ivey A, Vannucchi AM et al (2013) Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet\/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 27:2032. https:\/\/doi.org\/10.1038\/LEU.2013.219","journal-title":"Leukemia"},{"key":"771_CR15","doi-asserted-by":"publisher","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic\u00a0Neoplasms. Leukemia. https:\/\/doi.org\/10.1038\/S41375-022-01613-1","DOI":"10.1038\/S41375-022-01613-1"},{"key":"771_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/J.1365-2141.2007.06807.X","volume":"139","author":"DJ Kuter","year":"2007","unstructured":"Kuter DJ, Bain B, Mufti G et al (2007) Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 139:351\u2013362. https:\/\/doi.org\/10.1111\/J.1365-2141.2007.06807.X","journal-title":"Br J Haematol"},{"key":"771_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/AJH.25335","volume":"94","author":"AT Kuykendall","year":"2019","unstructured":"Kuykendall AT, Talati C, Padron E et al (2019) Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol 94:87\u201392. https:\/\/doi.org\/10.1002\/AJH.25335","journal-title":"Am J Hematol"},{"key":"771_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","volume":"136","author":"TS Larsen","year":"2007","unstructured":"Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N (2007) The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 136:745\u2013751. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06497.x","journal-title":"Br J Haematol"},{"key":"771_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0300060519891013","volume":"48","author":"B Li","year":"2020","unstructured":"Li B, Zou D, Yang S et al (2020) Meta-Analysis and Systematic Review Prognostic significance of U2AF1 mutations in myelodysplastic syndromes: a meta-analysis. J Int Med Res 48:1\u201312. https:\/\/doi.org\/10.1177\/0300060519891013","journal-title":"J Int Med Res"},{"key":"771_CR20","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/BLOOD-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R et al (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123:2220\u20132228. https:\/\/doi.org\/10.1182\/BLOOD-2013-11-537167","journal-title":"Blood"},{"key":"771_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/EJH.13005","volume":"100","author":"L Masarova","year":"2018","unstructured":"Masarova L, Alhuraiji A, Bose P et al (2018) Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia\/polycythemia vera myelofibrosis. Eur J Haematol 100:257. https:\/\/doi.org\/10.1111\/EJH.13005","journal-title":"Eur J Haematol"},{"key":"771_CR22","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1002\/CNCR.33094","volume":"126","author":"L Masarova","year":"2020","unstructured":"Masarova L, Bose P, Pemmaraju N et al (2020) Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer 126:4322. https:\/\/doi.org\/10.1002\/CNCR.33094","journal-title":"Cancer"},{"key":"771_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1309\/AJCP7D8ECZRXGWCG","volume":"139","author":"L Meintker","year":"2013","unstructured":"Meintker L, Ringwald J, Rauh M, Krause SW (2013) Comparison of automated differential blood cell counts from Abbott Sapphire, Siemens Advia 120, Beckman Coulter DxH 800, and Sysmex XE-2100 in normal and pathologic samples. Am J Clin Pathol 139:641\u2013650. https:\/\/doi.org\/10.1309\/AJCP7D8ECZRXGWCG","journal-title":"Am J Clin Pathol"},{"key":"771_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRANSCI.2022.103517","author":"M Merter","year":"2022","unstructured":"Merter M, Sahin U, Uysal S et al (2022) Role of large unstained cells in predicting successful stem cell collection in autologous stem cell transplantation. Transfus Apher Sci. https:\/\/doi.org\/10.1016\/J.TRANSCI.2022.103517","journal-title":"Transfus Apher Sci"},{"key":"771_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/EJH.12256","volume":"92","author":"O Moulard","year":"2014","unstructured":"Moulard O, Mehta J, Fryzek J et al (2014) Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 92:289\u2013297. https:\/\/doi.org\/10.1111\/EJH.12256","journal-title":"Eur J Haematol"},{"key":"771_CR26","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/BLOOD-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:1703\u20131708. https:\/\/doi.org\/10.1182\/BLOOD-2009-09-245837","journal-title":"Blood"},{"key":"771_CR27","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/BLOOD-2015-03-633404","volume":"126","author":"KP Patel","year":"2015","unstructured":"Patel KP, Newberry KJ, Luthra R et al (2015) Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126:790. https:\/\/doi.org\/10.1182\/BLOOD-2015-03-633404","journal-title":"Blood"},{"key":"771_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/AJH.25351","volume":"94","author":"D Penna","year":"2019","unstructured":"Penna D, Lasho TL, Finke CM et al (2019) 20+ Years and alive with primary myelofibrosis: phenotypic signature of very long-lived patients. Am J Hematol 94:286\u2013290. https:\/\/doi.org\/10.1002\/AJH.25351","journal-title":"Am J Hematol"},{"key":"771_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3324\/haematol.2011.051532","volume":"97","author":"M Pratcorona","year":"2012","unstructured":"Pratcorona M, Abbas S, Sanders MA et al (2012) Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica 97:388\u2013392. https:\/\/doi.org\/10.3324\/haematol.2011.051532","journal-title":"Haematologica"},{"key":"771_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/IJLH.12225","volume":"37","author":"E Rabizadeh","year":"2015","unstructured":"Rabizadeh E, Pickholtz I, Barak M et al (2015) Acute leukemia detection rate by automated blood count parameters and peripheral smear review. Int J Lab Hematol 37:44\u201349. https:\/\/doi.org\/10.1111\/IJLH.12225","journal-title":"Int J Lab Hematol"},{"key":"771_CR31","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/BLOOD-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi E, Cazzola M (2017) Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 129:680\u2013692. https:\/\/doi.org\/10.1182\/BLOOD-2016-10-695957","journal-title":"Blood"},{"key":"771_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/S12185-021-03239-Y","volume":"115","author":"N Saito","year":"2022","unstructured":"Saito N, Yamauchi T, Kawano N et al (2022) Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice. Int J Hematol 115:198. https:\/\/doi.org\/10.1007\/S12185-021-03239-Y","journal-title":"Int J Hematol"},{"key":"771_CR33","doi-asserted-by":"publisher","unstructured":"Shallis RM, Wang R, Davidoff A et al (2020) Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Rev 42. https:\/\/doi.org\/10.1016\/j.blre.2020.100706","DOI":"10.1016\/j.blre.2020.100706"},{"key":"771_CR34","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","volume":"25","author":"R Tamari","year":"2019","unstructured":"Tamari R, Rapaport F, Zhang N et al (2019) Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biol Blood Marrow Transplant 25:1142\u20131151. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.002","journal-title":"Biol Blood Marrow Transplant"},{"key":"771_CR35","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","volume":"23","author":"A Tefferi","year":"2005","unstructured":"Tefferi A (2005) Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23:8520\u20138530. https:\/\/doi.org\/10.1200\/JCO.2004.00.9316","journal-title":"J Clin Oncol"},{"key":"771_CR36","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D et al (2011) Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29:1356\u20131363. https:\/\/doi.org\/10.1200\/JCO.2010.32.9490","journal-title":"J Clin Oncol"},{"key":"771_CR37","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR et al (2014a) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124:2507\u20132513. https:\/\/doi.org\/10.1182\/blood-2014-05-579136","journal-title":"Blood"},{"issue":"28","key":"771_CR38","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"287","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM et al (2014b) (2014b) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leuk 287(28):1472\u20131477. https:\/\/doi.org\/10.1038\/leu.2014.3","journal-title":"Leuk"},{"issue":"32","key":"771_CR39","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","volume":"3210","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Finke CM, Lasho TL et al (2018a) (2018a) U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leuk 3210(32):2274\u20132278. https:\/\/doi.org\/10.1038\/s41375-018-0078-0","journal-title":"Leuk"},{"key":"771_CR40","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL et al (2018b) MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol 36:1769\u20131770. https:\/\/doi.org\/10.1200\/JCO.2018.78.9867","journal-title":"J Clin Oncol"},{"key":"771_CR41","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M et al (2018c) GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 32:1631\u20131642. https:\/\/doi.org\/10.1038\/s41375-018-0107-z","journal-title":"Leukemia"},{"key":"771_CR42","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F et al (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128\u20131132","journal-title":"Haematologica"},{"key":"771_CR43","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/CLINCHEM\/45.7.1100","volume":"45","author":"P Thirup","year":"1999","unstructured":"Thirup P (1999) LUC, what is that? Clin Chem 45:1100\u20131100. https:\/\/doi.org\/10.1093\/CLINCHEM\/45.7.1100","journal-title":"Clin Chem"},{"key":"771_CR44","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/AJH.23690","volume":"89","author":"GJ Titmarsh","year":"2014","unstructured":"Titmarsh GJ, Duncombe AS, Mcmullin MF et al (2014) How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 89:581\u2013587. https:\/\/doi.org\/10.1002\/AJH.23690","journal-title":"Am J Hematol"},{"issue":"9","key":"771_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-019-0175-y","volume":"92","author":"RR Vallapureddy","year":"2019","unstructured":"Vallapureddy RR, Mudireddy M, Penna D et al (2019) (2019) Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer J 92(9):1\u20138. https:\/\/doi.org\/10.1038\/s41408-019-0175-y","journal-title":"Blood Cancer J"},{"key":"771_CR46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000355184","volume":"131","author":"N Vanker","year":"2014","unstructured":"Vanker N, Ipp H (2014) Large unstained cells: a potentially valuable parameter in the assessment of immune activation levels in HIV infection. Acta Haematol 131:208\u2013212. https:\/\/doi.org\/10.1159\/000355184","journal-title":"Acta Haematol"},{"key":"771_CR47","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/LEU.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P et al (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27:1861\u20131869. https:\/\/doi.org\/10.1038\/LEU.2013.119","journal-title":"Leukemia"},{"key":"771_CR48","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/BLOOD-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951. https:\/\/doi.org\/10.1182\/BLOOD-2009-03-209262","journal-title":"Blood"},{"key":"771_CR49","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/S00277-020-04387-7","volume":"100","author":"Z Wang","year":"2021","unstructured":"Wang Z, Liu W, Wang M et al (2021) Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis. Ann Hematol 100:465\u2013479. https:\/\/doi.org\/10.1007\/S00277-020-04387-7","journal-title":"Ann Hematol"}],"container-title":["Journal of Applied Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-023-00771-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13353-023-00771-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-023-00771-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T01:05:55Z","timestamp":1693011955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13353-023-00771-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s13353-023-00771-x","relation":{},"ISSN":["1234-1983","2190-3883"],"issn-type":[{"value":"1234-1983","type":"print"},{"value":"2190-3883","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"assertion":[{"value":"11 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The protocol of the study was approved by the Ethics Committee of Pozna\u0144 University of Medical Sciences (number: 1056\/16, 181\/18 and 846\/21).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}